Devices › Lenses, soft contact, daily wear
Device brand name · Lpl soft contact lens daily wear
Avaira Sphere Enfilcon A: medical device reports filed with FDA
158 reports name it, 2011–2018. Manufacturer given most often on reports: Coopervision Manufacturing. Product code LPL.
- 158
- device reports naming the brand
- 0% of all MAUDE reports · about 10 a year
- 0
- reports, 12 months to August 2026
- 0 in the 12 months before
- 0%
- classified as malfunction
- 4.9% across the product code
- 0%
- classified as death, as reported
- 0 reports · not verified by FDA
158 medical device reports received by FDA name the brand "Avaira Sphere Enfilcon A" (lpl soft contact lens daily wear); the manufacturer given most often on reports is Coopervision Manufacturing; received from June 2011 to December 2018. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.
0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (100%); across all lenses, soft contact, daily wear reports (product code LPL) death is recorded in 0% and malfunction in 4.9%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are insufficient device problem information (69.6%), improper or incorrect procedure or method (3.2%) and device operates differently than expected (2.5%). The patient problems coded most often are corneal ulcer, red eye(s) and blurred vision. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
No report naming Avaira Sphere Enfilcon A was received in the five years to August 2026; the latest was received in December 2018.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 4,882 reports carrying product code LPL. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Insufficient device problem information | 110 | 69.6% | 13.4% |
| Improper or incorrect procedure or method | 5 | 3.2% | 2.5% |
| Device operates differently than expectedthe device behaved unexpectedly | 4 | 2.5% | 2.9% |
| Nonstandard device | 3 | 1.9% | 1.9% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Corneal ulcer | 34 | 21.5% |
| Red eye(s) | 24 | 15.2% |
| Blurred vision | 15 | 9.5% |
| Corneal abrasion | 15 | 9.5% |
| Painpain, site not specified | 13 | 8.2% |
| Keratitis | 12 | 7.6% |
| Corneal scar | 11 | 7% |
| Irritationirritation | 11 | 7% |
| Intraocular infection | 8 | 5.1% |
| Conjunctivitispink eye | 7 | 4.4% |
| Iritis | 6 | 3.8% |
| Discharge | 5 | 3.2% |
| Burning sensationa burning feeling | 4 | 2.5% |
| Scarring | 4 | 2.5% |
| Bacterial infectiona bacterial infection | 3 | 1.9% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Avaira Sphere Enfilcon A | Product code LPL | All MAUDE reports |
|---|---|---|---|
| Reports | 158 | 4,882 | 26,136,888 |
| Share of that pool | — | 3.2% | 0% |
| Classified as death, per 1,000 reports | 0 | 0 | 9 |
| Classified as injury | 100% | 90.9% | 36.2% |
| Classified as malfunction | 0% | 4.9% | 62.3% |
| Filed by the manufacturer | 100% | 79.4% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code LPL
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Acuvue Oasys | 719 | 27 | 0% |
| Dailies Total 1 | 195 | 12 | 0% |
| Air Optix Night & Day Aqua | 151 | 9 | 0% |
| Focus Night & Day | 215 | 0 | 0% |
| Acuvue 2 | 174 | 5 | 0% |
| ACUVUE OASYS for ASTIGMATISM | 261 | 18 | 0% |
| Complete Moisture Plus | 188 | 0 | 0% |
| AdvanCE | 220 | 8 | 2.7% |
| Biofinity Toric (comfilcon A) | 212 | 16 | 0% |
| Amo Complete Moisture Plus | 174 | 0 | 0% |
| Ciba Vision Memory Lens | 294 | 0 | 0% |
| Clear Care | 264 | 0 | 0% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Avaira Sphere Enfilcon A reports
How many FDA reports name Avaira Sphere Enfilcon A?
158 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.
What kinds of events are reported?
injury (100%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
insufficient device problem information (69.6%), improper or incorrect procedure or method (3.2%), device operates differently than expected (2.5%) and nonstandard device (1.9%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Avaira Sphere Enfilcon A was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.